Neurimmune to receive a milestone payment from Ono Pharmaceuticals

Neurimmune develops innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine (RTM) platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.

In November 2017, the company signed a partnership with the Japanese based Ono Pharmaceuticals focused on the development of human-derived antibodies against a novel therapeutic target for neurodegenerative diseases. Under the terms of the collaboration agreement Neurimmune would conduct research to generate and validate human-derived monoclonal antibodies using its RTM technology platform. The milestone triggers a pre-agreed milestone payment to Neurimmune.

“We highly appreciate a key success in drug discovery of human-derived monoclonal antibodies with Neurimmune’s platform”, said Hiromu Habashita, Corporate Officer and Executive Director, Discovery and Research of Ono. “We believe this progress will lead to the delivery of a novel and innovative treatment for patients with neurodegenerative diseases.”

“We highly value the collaborative nature of our partnership with Ono, a global pioneer of innovative medicines”, said Jan Grimm, Chief Scientific Officer and co-founder of Neurimmune. “We are excited about the rapid progress within the first year of this collaboration and look forward to advance novel human-derived antibody candidates for CNS indications of high unmet medical need.”

Ono will be responsible for worldwide development and marketing of products derived from this collaboration. Neurimmune is eligible to receive research fees, success-based milestones on the research and development progress, as well as royalties on product sales.

Photo: Neurimmune's Reverse Translational Medicine.

(Press release/ran)